CXCR5 and neoplasm: The results of in vivo CAR-T tracking experiments showed that CAR-T cells modified with CXCR5 can migrate and infiltrate toward tumor lesions in a targeted manner, significantly clearing the tumor while greatly reducing potential extratumoral toxicity (78).